<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.trials.v2.TrialResultsOutput xmlns:ns2="local" hits="1" offset="0" totalResults="1"><Filters total="48"><Filter label="Trial Technologies" name="trialTechnologies" total="3"><FilterOption id="586" count="1" label="Capsule formulation"></FilterOption><FilterOption id="585" count="1" label="Oral formulation"></FilterOption><FilterOption id="762" count="1" label="Small molecule therapeutic"></FilterOption></Filter><Filter label="Indications" name="indications" total="1"><FilterOption id="245" count="1" label="Osteoarthritis"></FilterOption></Filter><Filter label="Endpoint Index" name="trialEndpointIndex" total="0"></Filter><Filter label="Trial Drug Phase Highest" name="trialDrugPhaseHighest" total="1"><FilterOption id="L" count="1" label="Launched"></FilterOption></Filter><Filter label="Trial Company Sponsor" name="trialCompaniesSponsor" total="1"><FilterOption id="18767" count="1" label="Pfizer Inc"></FilterOption></Filter><Filter label="Trial Recruitment Status" name="trialRecruitmentStatus" total="1"><FilterOption id="12" count="1" label="Status not specified"></FilterOption></Filter><Filter label="Trial Commercially Significant" name="trialIsCommerciallySignificant" total="1"><FilterOption id="YES" count="1" label="Yes"></FilterOption></Filter><Filter label="Trial Indications Pioneer" name="trialIndicationsPioneer" total="0"></Filter><Filter label="Registry Id" name="trialRegistries" total="0"></Filter><Filter label="Trial Reason for Discontinuation" name="trialReasonForDiscontinuation" total="0"></Filter><Filter label="Active Controls" name="trialActiveControls" total="0"></Filter><Filter label="Exclusion Criteria Index" name="trialExclusionCriteriaIndex" total="0"></Filter><Filter label="Trial Date Enrollment End By Month" name="trialDateEnrollmentEndByMonth" total="0"></Filter><Filter label="Funder Type" name="trialFunderType" total="1"><FilterOption id="CMP" count="1" label="Company"></FilterOption></Filter><Filter label="Trial Region" name="trialRegions" total="1"><FilterOption id="USCA" count="1" label="US &amp; Canada"></FilterOption></Filter><Filter label="Patient Segment Index" name="trialPatientSegmentIndex" total="0"></Filter><Filter label="Primary Completion Filter by Month" name="trialPrimaryCompletionDateByMonth" total="0"></Filter><Filter label="Trial Country" name="trialCountries" total="1"><FilterOption id="US" count="1" label="US"></FilterOption></Filter><Filter label="Trial Patient Selection" name="trialTermsPatientSelection" total="0"></Filter><Filter label="Trial Terms Design" name="trialTermsDesign" total="6"><FilterOption id="SSTINV" count="1" label="Interventional"></FilterOption><FilterOption id="SIMMBD" count="1" label="Multiple Blind"></FilterOption><FilterOption id="SISPRL" count="1" label="Parallel Assignment"></FilterOption><FilterOption id="SICPLC" count="1" label="Placebo Control"></FilterOption><FilterOption id="SIARND" count="1" label="Randomized"></FilterOption><FilterOption id="SIPTRE" count="1" label="Treatment"></FilterOption></Filter><Filter label="Trial Source" name="trialSources" total="1"><FilterOption id="OTHERS" count="1" label="Others only"></FilterOption></Filter><Filter label="Trial Actions Secondary Interventions Primary" name="trialActionsSecondaryInterventionsPrimary" total="3"><FilterOption id="2946" count="1" label="Analgesic"></FilterOption><FilterOption id="1545" count="1" label="Anticancer"></FilterOption><FilterOption id="2955" count="1" label="Non-steroidal anti-inflammatory"></FilterOption></Filter><Filter label="Trial Endpoint Achieved" name="trialEndpointsAchieved" total="1"><FilterOption id="UNSPECIFIED" count="1" label="Unspecified"></FilterOption></Filter><Filter label="Endpoint Index Secondary" name="trialEndpointIndexSecondary" total="0"></Filter><Filter label="Biomarker" name="trialBiomarkerNames" total="0"></Filter><Filter label="Trial Terms Endpoint" name="trialTermsEndpoint" total="2"><FilterOption id="SIEEFC" count="1" label="Efficacy"></FilterOption><FilterOption id="SIESFT" count="1" label="Safety"></FilterOption></Filter><Filter label="Trial Interventions Primary In Regimen Name Display" name="trialInterventionsPrimaryInRegimenNameDisplay" total="0"></Filter><Filter label="Trial Document Source" name="trialDocumentSource" total="1"><FilterOption id="SERIAL" count="1" label="Serial Publications"></FilterOption></Filter><Filter label="Trial Interventions Primary Alone Name Display" name="trialInterventionsPrimaryAloneNameDisplay" total="1"><FilterOption id="12135" count="1" label="celecoxib"></FilterOption></Filter><Filter label="Trial Interventions Control In Regimen Name Display" name="trialInterventionsControlInRegimenNameDisplay" total="0"></Filter><Filter label="Trial Category" name="trialCategory" total="1"><FilterOption id="4" count="1" label="Small molecule"></FilterOption></Filter><Filter label="Trial Outcome Available" name="trialOutcomesAvailable" total="1"><FilterOption id="YES" count="1" label="Yes"></FilterOption></Filter><Filter label="Trial Actions Primary Interventions Primary" name="trialActionsPrimaryInterventionsPrimary" total="1"><FilterOption id="1001" count="1" label="Cyclooxygenase 2 inhibitor"></FilterOption></Filter><Filter label="Trial Company Collaborator" name="trialCompaniesCollaborator" total="0"></Filter><Filter label="Trial Actions Secondary Interventions Control" name="trialActionsSecondaryInterventionsControl" total="0"></Filter><Filter label="Biomarker Type" name="trialBiomarkerTypes" total="0"></Filter><Filter label="Biomarker Role" name="trialBiomarkerRoles" total="0"></Filter><Filter label="Interventions" name="trialInterventions" total="1"><FilterOption id="12135" count="1" label="celecoxib"></FilterOption></Filter><Filter label="Endpoint Index Primary" name="trialEndpointIndexPrimary" total="0"></Filter><Filter label="Sponsors/Collaborators" name="trialCompanies" total="1"><FilterOption id="18767" count="1" label="Pfizer Inc"></FilterOption></Filter><Filter label="Last Changed Date By Day" name="trialDateChangeLastByDay" total="1"><FilterOption count="1" label="2011-08-18"></FilterOption></Filter><Filter label="Trial Date End By Month" name="trialDateEndByMonth" total="0"></Filter><Filter label="Trial Date Start By Month" name="trialDateStartByMonth" total="1"><FilterOption count="1" label="199906"></FilterOption></Filter><Filter label="Trial Phase" name="trialPhase" total="1"><FilterOption id="C3B" count="1" label="Phase 3b Clinical"></FilterOption></Filter><Filter label="Inclusion Criteria Index" name="trialInclusionCriteriaIndex" total="0"></Filter><Filter label="Trial Interventions Control Alone Name Display" name="trialInterventionsControlAloneNameDisplay" total="0"></Filter><Filter label="Trial Actions Primary Interventions Control" name="trialActionsPrimaryInterventionsControl" total="0"></Filter><Filter label="Trial Indications Adverse" name="trialIndicationsAdverse" total="7"><FilterOption id="3472" count="1" label="Abdominal pain"></FilterOption><FilterOption id="102" count="1" label="Diarrhea"></FilterOption><FilterOption id="3454" count="1" label="Dizziness"></FilterOption><FilterOption id="432" count="1" label="Dyspepsia"></FilterOption><FilterOption id="148" count="1" label="Headache"></FilterOption><FilterOption id="226" count="1" label="Nausea"></FilterOption><FilterOption id="516" count="1" label="Upper respiratory tract infection"></FilterOption></Filter></Filters><SearchResults><Trial Id="80131"><Indications><Indication>Osteoarthritis</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Cyclooxygenase 2 inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Analgesic</Action><Action>Anticancer</Action><Action>Non-steroidal anti-inflammatory</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>Pfizer Inc</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2011-08-18T00:00:00Z</DateChangeLast><DateStart>1999-06-09T00:00:00Z</DateStart><Identifiers><Identifier>A3191314</Identifier><Identifier>N49-98-02-118</Identifier></Identifiers><IndicationsAdverse><Indication>Abdominal pain</Indication><Indication>Diarrhea</Indication><Indication>Dizziness</Indication><Indication>Dyspepsia</Indication><Indication>Headache</Indication><Indication>Nausea</Indication><Indication>Upper respiratory tract infection</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>celecoxib alone</Intervention><Intervention>diclofenac alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>600</PatientCountEnrollment><Phase>Phase 3b Clinical</Phase><RecruitmentStatus>Status not specified</RecruitmentStatus><Teaser>The purpose of this phase IIIb, double-blind, placebo-controlled, randomized clinical trial was to compare the efficacy and safety of celecoxib and diclofenac for the treatment of patients with signs and symptoms of osteoarthritis of the knee [ 1215867 ], [ 1215868 ].</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TitleDisplay>A phase IIIb, double-blind, placebo-controlled, randomized clinical trial to compare the efficacy and safety of celecoxib and diclofenac for the treatment of patients with signs and symptoms of osteoarthritis of the knee</TitleDisplay><PrimaryCompletionDate></PrimaryCompletionDate><NumberOfSites>1</NumberOfSites></Trial></SearchResults></ns2:com.thomsonreuters.ls.service.contract.soap.trials.v2.TrialResultsOutput>